Is Breast Cancer in Men Curable?

Yes. And the survival rates, when the disease is caught early, are genuinely high above 90% at five years for Stage 1 and Stage 2 disease. The problem is that men almost never catch it early, because most men don’t know they can get breast cancer at all.Less than 1% of all breast cancers are diagnosed in men. That rarity is exactly what makes it dangerous. A man finds a firm lump near the nipple and assumes it’s a cyst, a minor infection, something that will go away on its own. He waits. Sometimes for months. By the time he sees a doctor, the cancer has often had time to progress beyond where it was when he first noticed it. The biology of male breast cancer is not inherently worse than female breast cancer; the tumour types, the receptor profiles, and the treatment responses are broadly similar. What’s worse is the delay. And the delay comes from not knowing this is something men need to check.

According to Dr. Sandeep Nayak, Best Cancer Treatment in Bangalore, “Male breast cancer is rare enough that most men never think about it, and most GPs don’t immediately consider it either. But the treatment follows the same principles as female breast cancer, the drugs work the same way, and the survival rates for early-stage disease are comparable. The patients who do poorly are the ones diagnosed late — not because the cancer is untreatable, but because time was lost before treatment started.”

Stage at diagnosis is the dominant factor
Stage 1 five-year survival in men runs above 96%. Stage 2 sits around 84% to 91%. By Stage 3, that drops to around 60% to 70%, and Stage 4 — metastatic disease — is managed rather than cured in most cases. None of those numbers are unique to male breast cancer. They reflect what happens in virtually every solid tumour when treatment starts earlier versus later. For male breast cancer, the challenge is that later diagnosis is the norm rather than the exception.

Receptor status determines which treatments work
Over 90% of male breast cancers are hormone receptor-positive. That’s a higher rate than in women. It means tamoxifen — the same drug used in pre-menopausal women with hormone receptor-positive disease — is the standard adjuvant hormonal treatment for most men after surgery, typically for five to ten years. A smaller proportion of male breast cancers are HER2-positive, which opens access to anti-HER2 therapy with the same efficacy seen in women.

Surgery is almost always part of the plan
Because men have very little breast tissue, the tumour typically sits close to the nipple and chest wall. Modified radical mastectomy removal of the breast tissue with axillary lymph node dissection  is the standard surgical approach in most male breast cancer cases. Breast-conserving surgery is occasionally possible in early, small tumours, but it’s technically less applicable than in women with larger breast volume. The surgical oncological principles are the same regardless.

BRCA status matters more in men than most realise
BRCA2 mutations are found in roughly 10% of male breast cancer cases, a much higher proportion than in the general male population. A man with a BRCA2 mutation has a lifetime breast cancer risk of around 6% to 8%, compared to a fraction of a percent in the general population. BRCA testing at diagnosis isn’t optional in male breast cancer; it changes the surveillance plan for the patient and has direct implications for first-degree relatives. Germline testing should happen regardless of family history.

Surgery first in most cases
Modified radical mastectomy with sentinel node biopsy or axillary dissection depending on nodal status. Where sentinel node biopsy is appropriate clinically node-negative axilla that’s the approach taken to avoid the lymphoedema risk that comes with full dissection.

Hormone therapy for the majority
Tamoxifen for five to ten years post-surgery is standard for hormone receptor-positive disease. Aromatase inhibitors are used in some cases, though the evidence base in men is less robust than tamoxifen, and they’re generally combined with a GnRH agonist to adequately suppress oestrogen production in men.

Chemotherapy when indicated
The indications for adjuvant chemotherapy in male breast cancer follow the same criteria as in women — tumour size, nodal involvement, grade, receptor status, and genomic risk scores where available. Neoadjuvant chemotherapy before surgery is used for larger tumours where shrinking the disease first changes what surgery can achieve.

Radiation
Post-mastectomy radiation is indicated for the same reasons it is in women  positive margins, significant nodal involvement, or large primary tumours. The field and technique are the same.

For a comprehensive look at what male breast cancer actually involves, why it gets missed, and how the diagnosis is typically made, the previous blog on Can Breast Cancer Occur in Men covers the full clinical picture in detail.

Dr. Sandeep Nayak’s team at MACS Clinic treats male breast cancer with the same tumour board review process applied to every breast cancer case  receptor status confirmed, BRCA testing initiated, surgical plan built around staging and response, and systemic treatment sequenced correctly before the operation is planned.

Male breast cancer is rare enough that experience matters more here, not less. Men who present with a chest lump, nipple change, or a family history that puts them at elevated risk can discuss their case directly with the team. Reach them at +91 8035740000.

References

1. National Cancer Institute. Male Breast Cancer Treatment. https://www.cancer.gov/types/breast/patient/male-breast-treatment-pdq
2. Giordano SH. Breast Cancer in Men. New England Journal of Medicine, 2018. https://www.nejm.org/doi/full/10.1056/NEJMra1707939

Disclaimer:This content is published for educational and informational purposes only.